Compare CDNA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | OGN |
|---|---|---|
| Founded | 1998 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2007 | 2020 |
| Metric | CDNA | OGN |
|---|---|---|
| Price | $49.77 | $13.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $28.00 | $11.40 |
| AVG Volume (30 Days) | 970.3K | ★ 3.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | 0.95 |
| Revenue | $48,324,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $16.01 | $0.45 |
| Revenue Next Year | $11.31 | $1.67 |
| P/E Ratio | $22.94 | ★ $14.49 |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $13.39 | $5.69 |
| 52 Week High | $53.67 | $13.79 |
| Indicator | CDNA | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 74.71 |
| Support Level | $44.80 | $13.46 |
| Resistance Level | $49.76 | N/A |
| Average True Range (ATR) | 2.51 | 0.03 |
| MACD | -0.51 | -0.00 |
| Stochastic Oscillator | 45.88 | 91.67 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.